3 hours ago
1
Veronique D
Sanofi (NASDAQ:SNY) said on Wednesday that Tzield was approved in China as the first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes.
Approval is based on the TN-10 study, demonstrating Tzield’s ability to delay the onset
© FBT Company 2025. All rights are reserved
English (US) ·